Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

In this episode, David M. Schuster, MD, FACR, highlights the recent FDA approval of flotufolastat F 18 (POSLUMA), a PSMA-PET imaging agent in prostate cancer. Schuster is a professor of radiology and imaging sciences and the director of the division of nuclear medicine and molecular imaging at Emory University School of Medicine in Atlanta, Georgia.